ImmunityBio (IBRX) Share-based Compensation (2014 - 2026)

ImmunityBio (IBRX) has reported Share-based Compensation for 13 consecutive years, with $16.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation changed N/A year-over-year to $16.4 million; the TTM figure through Mar 2026 stood at $22.3 million (up 107.16% YoY), while the FY2025 annual figure was $5.9 million, down 59.63% from the prior year.
• Share-based Compensation advanced to $16.4 million in Q1 2026 per IBRX's latest filing, from -$22.2 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $26.5 million in Q3 2025 and bottomed at -$22.2 million in Q4 2025.
• Historically, Share-based Compensation has averaged $3.0 million across 5 years, with a median of $2.7 million in 2024.
• On a YoY basis, Share-based Compensation climbed as much as 2824.19% in 2023 and fell as far as 69840.0% in 2023.
• ImmunityBio's Share-based Compensation stood at -$10.0 million in 2022, then jumped by 185.41% to $8.6 million in 2023, then grew by 16.16% to $10.0 million in 2024, then tumbled by 322.47% to -$22.2 million in 2025, then soared by 173.91% to $16.4 million in 2026.
• Business Quant data shows IBRX's Share-based Compensation at $16.4 million in Q1 2026, -$22.2 million in Q4 2025, and $26.5 million in Q3 2025.